Literature DB >> 30654830

Potential confounders for the effect of high-flow nasal cannula oxygen therapy.

Satoshi Yamaga1, Shinichiro Ohshimo2, Nobuaki Shime1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30654830      PMCID: PMC6337845          DOI: 10.1186/s13054-019-2310-3

Source DB:  PubMed          Journal:  Crit Care        ISSN: 1364-8535            Impact factor:   9.097


× No keyword cloud information.
To the Editor: We read with considerable interest the article published in a recent issue of Critical Care by Di Mussi and colleagues [1], who investigated the physiological effects of high-flow nasal canula (HFNC) compared with conventional O2 therapy after extubation in patients with chronic obstructive pulmonary disease (COPD) receiving mechanical ventilation. The authors demonstrated that postextubation HFNC significantly decreased neuroventilatory drive and the work of breathing compared with conventional O2 therapy. However, several factors that might potentially affect their results should be discussed. First, although the authors discussed one of the mechanisms related to the decreased work of breathing using HFNC compared with conventional O2 therapy, which was associated with the flow-dependent CO2 wash-out effect, they did not directly assess the relationship between the variables of work of breathing and the flow rate of HFNC. Various flow rates ranging from 20 to 60 L/min were used in this study, which are inconsistent with previous studies, where the flow rates of HFNC were fixed [2, 3]. A higher flow rate of HFNC potentially increases the CO2 wash-out effect and consequently decreases the respiratory effort [4]. Second, the reasons for reintubation in this study were unclear. The authors failed to show a correlation between the work of breathing and the requirement of reintubation; more significant risk factors of reintubation could include other clinical conditions. Shock or disturbed consciousness, masking the effect of HFNC, might be potential confounders in this study. Finally, we would like to know the differences in clinical characteristics between the patients who benefited from HFNC and those who did not. The authors demonstrated that several patients showed almost no change in neuroventilatory drive and work of breathing independent of the use of HFNC or conventional O2 therapy. We speculate that the strength of respiratory drive or the severity of COPD affected these parameters. In conclusion, we believe that clarification of these issues by the authors would be helpful for a better understanding of the benefit of postextubation HFNC in patients with COPD.
  4 in total

1.  High-flow nasal cannula versus conventional oxygen therapy after endotracheal extubation: a randomized crossover physiologic study.

Authors:  Nuttapol Rittayamai; Jamsak Tscheikuna; Pitchayapa Rujiwit
Journal:  Respir Care       Date:  2013-09-17       Impact factor: 2.258

2.  Nasal high-flow versus Venturi mask oxygen therapy after extubation. Effects on oxygenation, comfort, and clinical outcome.

Authors:  Salvatore Maurizio Maggiore; Francesco Antonio Idone; Rosanna Vaschetto; Rossano Festa; Andrea Cataldo; Federica Antonicelli; Luca Montini; Andrea De Gaetano; Paolo Navalesi; Massimo Antonelli
Journal:  Am J Respir Crit Care Med       Date:  2014-08-01       Impact factor: 21.405

3.  Optimum support by high-flow nasal cannula in acute hypoxemic respiratory failure: effects of increasing flow rates.

Authors:  Tommaso Mauri; Laura Alban; Cecilia Turrini; Barbara Cambiaghi; Eleonora Carlesso; Paolo Taccone; Nicola Bottino; Alfredo Lissoni; Savino Spadaro; Carlo Alberto Volta; Luciano Gattinoni; Antonio Pesenti; Giacomo Grasselli
Journal:  Intensive Care Med       Date:  2017-07-31       Impact factor: 17.440

4.  High-flow nasal cannula oxygen therapy decreases postextubation neuroventilatory drive and work of breathing in patients with chronic obstructive pulmonary disease.

Authors:  Rosa Di Mussi; Savino Spadaro; Tania Stripoli; Carlo Alberto Volta; Paolo Trerotoli; Paola Pierucci; Francesco Staffieri; Francesco Bruno; Luigi Camporota; Salvatore Grasso
Journal:  Crit Care       Date:  2018-08-02       Impact factor: 9.097

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.